Edition:
United Kingdom

Bioverativ Inc (BIVV.OQ)

BIVV.OQ on NASDAQ Stock Exchange Global Select Market

53.21USD
15 Dec 2017
Change (% chg)

$-0.26 (-0.49%)
Prev Close
$53.47
Open
$53.53
Day's High
$53.74
Day's Low
$52.67
Volume
2,632,365
Avg. Vol
390,139
52-wk High
$64.40
52-wk Low
$41.21

Latest Key Developments (Source: Significant Developments)

Bioverativ’s BIVV009 achieves positive results in Phase 1B CAgD patients
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Bioverativ Inc ::BIOVERATIV’S INVESTIGATIONAL BIVV009 DEMONSTRATES SAFETY, TOLERABILITY AND EFFICACY IN PHASE 1B CLINICAL TRIAL IN COLD AGGLUTININ DISEASE (CAGD) PATIENTS.BIOVERATIV INC - PHASE 1B RESULTS ACHIEVE PRIMARY AND SECONDARY ENDPOINTS IN CAGD COHORT.BIOVERATIV - FOUND STATISTICALLY SIGNIFICANT OVERALL INCREASED RATE OF THROMBOEMBOLIC EVENTS IN CAGD PATIENTS VERSUS MATCHED CONTROLS.  Full Article

Bioverativ says U.S. ‍FDA Has Approved Updated Labeling For Alprolix ​
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Bioverativ Inc ::BIOVERATIV INC - U.S. ‍FDA HAS APPROVED UPDATED LABELING FOR ALPROLIX ​.BIOVERATIV INC SAYS LABEL UPDATE INCLUDES ADDITION OF PEDIATRIC DATA RELATED TO PROPHYLACTIC TREATMENT WITH ALPROLIX.  Full Article

Bioverativ reports Q3 earnings per share $0.63
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Bioverativ Inc :Bioverativ reports third quarter 2017 performance.Q3 non-gaap earnings per share $0.80.Q3 gaap earnings per share $0.63.Q3 revenue $291.6 million versus i/b/e/s view $285.5 million.Q3 earnings per share view $0.69 -- Thomson Reuters I/B/E/S.  Full Article

Valueact Capital Management LLC reports 3.8 pct stake in Bioverativ Inc as of July 13 - SEC filing
Monday, 17 Jul 2017 

July 17 (Reuters) - Bioverativ Inc :Valueact Capital Management LLC reports 3.8 percent stake in Bioverativ Inc as of July 13 versus 7.5 percent stake as of Feb 28 - SEC filing.  Full Article

Primecap Management Company reports 7.19 pct passive stake in Bioverativ - SEC filing
Monday, 6 Mar 2017 

Bioverativ Inc:Primecap management company reports a 7.19 percent passive stake in bioverativ inc as of feb 28, 2017- SEC filing.  Full Article

BRIEF-Bioverativ’s BIVV009 achieves positive results in Phase 1B CAgD patients

* BIOVERATIV’S INVESTIGATIONAL BIVV009 DEMONSTRATES SAFETY, TOLERABILITY AND EFFICACY IN PHASE 1B CLINICAL TRIAL IN COLD AGGLUTININ DISEASE (CAGD) PATIENTS